SPI-119

N/A

Report date: 2024/12/18 13:39:48
NME

Base Information

Drug NameSPI-119
Drug Alias NameRBC CD4 liposomalCD4-liposomal
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionT-cell surface antigen CD4 agonists
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSheffield Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlza Corporation, De, Usa
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A